# ğŸ¯ PPN RESEARCH PORTAL - EXECUTIVE PITCH DECK

**Presentation for:** Clinical Network Leaders, NIH Leadership, Strategic Partners  
**Prepared by:** Trevor Calton, Founder  
**Date:** February 2026  
**Version:** 1.0 - Executive Briefing

---

## SLIDE 1: TITLE

# **PPN Research Portal**
## The Clinical Intelligence Platform for Psychedelic Therapy

**Tagline:** *"See what works. Before you treat."*

**Presenter:** Trevor Calton  
**Contact:** [Your contact info]

---

## SLIDE 2: THE PROBLEM (Dr. Shena's Voice)

### **"Research progress is hampered by lack of comparable data"**
*â€” Dr. Shena Jaramillo, Bend Ketamine Clinic*

**The Current Reality:**

- âŒ **No common data collection framework** across clinics
- âŒ **Each practitioner using different assessment tools**
- âŒ **Impossible to compare protocols or outcomes**
- âŒ **No way to identify best practices**
- âŒ **Evidence base remains fragmented**

**Impact:**
- Practitioners making decisions in isolation
- Patients receiving inconsistent care
- Field advancement slowed by 10-20 years
- Legislative change lacks compelling evidence

---

## SLIDE 3: THE PRECEDENT (Dr. Fadiman's Model)

### **Dr. James Fadiman: 17 Years of Anonymous Data Collection**

**What he proved:**
- âœ… Systematic data collection works (microdosing evidence base)
- âœ… Anonymous reporting generates participation
- âœ… Aggregated data drives field forward
- âœ… No institutional backing required

**What he couldn't do:**
- âŒ Real-time feedback to practitioners
- âŒ Comparative effectiveness analysis
- âŒ Protocol optimization at scale
- âŒ Clinical decision support

**Our Opportunity:**  
*"What took Dr. Fadiman 17 years, we can do in 17 months â€” and give practitioners real-time intelligence."*

---

## SLIDE 4: WHAT WE'RE BUILDING

# **Clinical Intelligence Platform**
## Not an EHR. Not Practice Management. Something New.

### **What It IS:**
âœ… Real-time benchmarking network  
âœ… Clinical decision support system  
âœ… Predictive outcome modeling  
âœ… Research infrastructure  
âœ… Quality improvement tool  

### **What It's NOT:**
âŒ Electronic Health Record (EHR)  
âŒ Practice management system  
âŒ Patient portal  
âŒ Document storage  
âŒ PHI repository  

**Strategic Positioning:**  
*"The intersection of clinical utility and research rigor that doesn't exist today."*

---

## SLIDE 5: HOW IT WORKS (The Interface)

### **Split-Screen Clinical Intelligence**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  PRACTITIONER INPUTS    â”‚  LIVE DATA INTELLIGENCE      â”‚
â”‚  (Planning Protocol)    â”‚  (Real-Time Benchmarking)    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                         â”‚                              â”‚
â”‚ Patient Profile:        â”‚ ğŸ“Š Similar Patients (N=127)  â”‚
â”‚ â€¢ Age: 36-45           â”‚ â€¢ 68% significant improvementâ”‚
â”‚ â€¢ Indication: MDD      â”‚ â€¢ 24% moderate improvement   â”‚
â”‚ â€¢ Weight: 61-70 kg     â”‚ â€¢ 8% minimal improvement     â”‚
â”‚                         â”‚                              â”‚
â”‚ Proposed Protocol:      â”‚ ğŸ§  Receptor Impact           â”‚
â”‚ â€¢ Ketamine 0.5mg/kg    â”‚ â€¢ NMDA: 80% antagonism       â”‚
â”‚ â€¢ IV infusion          â”‚ â€¢ AMPA: 60% activation       â”‚
â”‚ â€¢ 45 minutes           â”‚ â€¢ mTOR: 40% pathway activity â”‚
â”‚                         â”‚                              â”‚
â”‚ Concomitant Meds:       â”‚ âš ï¸ Safety Alert              â”‚
â”‚ â€¢ Benzodiazepines      â”‚ â€¢ May reduce efficacy (23%)  â”‚
â”‚                         â”‚ â€¢ Consider holding 24h       â”‚
â”‚                         â”‚                              â”‚
â”‚ [Save Plan] [Submit]    â”‚ ğŸ“ˆ Network Benchmarks        â”‚
â”‚                         â”‚ â€¢ Your clinic: 72% success   â”‚
â”‚                         â”‚ â€¢ Network avg: 68% success   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Key Innovation:**  
*Inputs simultaneously act as filters on real-time data visualization*

---

## SLIDE 6: THE CLINICAL WORKFLOW TRANSFORMATION

### **BEFORE: Retroactive Logging**
1. Practitioner designs protocol (in isolation)
2. Delivers treatment
3. Logs data weeks later
4. Sees benchmarks months later
5. **Value: Minimal** (too late to inform decisions)

---

### **AFTER: Prospective Intelligence**

**BEFORE Treatment:**
1. Practitioner enters patient profile
2. **System shows:** Similar patients' outcomes (N=127, 68% success)
3. Practitioner enters proposed protocol
4. **System shows:** Receptor targets, safety alerts, network benchmarks
5. Practitioner adjusts protocol based on data
6. **Practitioner shows patient:** "Here's why we're choosing this approach"
7. Saves "planned protocol"

**AFTER Treatment:**
8. Logs actual treatment + outcomes
9. **System compares:** Planned vs Actual
10. **System learns:** Updates predictive models

**Value: Transformative** (every decision informed by network intelligence)

---

## SLIDE 7: THE MOAT (Network Effects)

### **Why This Gets Stronger Over Time**

**Traditional Software:** Value is static  
**Network Platform:** Value compounds with every user

```
Network Size â†’ Data Quality â†’ Predictive Accuracy â†’ Clinical Value â†’ More Users â†’ Repeat

Week 1:   10 sites  â†’  N=50   â†’  Low confidence  â†’  Modest value
Month 6:  50 sites  â†’  N=500  â†’  Medium confidence â†’  High value
Year 2:   150 sites â†’  N=5000 â†’  High confidence  â†’  Indispensable
```

**The Compounding Effect:**
- More practitioners = More data
- More data = Better predictions
- Better predictions = Higher value
- Higher value = More practitioners

**Defensibility:**  
*"First mover advantage in psychedelic benchmarking is a 5-10 year moat"*

---

## SLIDE 8: WHY NO PHI? (Strategic Advantage)

### **This Isn't Caution. It's Strategy.**

| **With PHI (EHR Model)** | **Without PHI (Our Model)** |
|--------------------------|------------------------------|
| âŒ HIPAA compliance required | âœ… No HIPAA requirements |
| âŒ $500K/year ongoing cost | âœ… $0 compliance overhead |
| âŒ Breach liability: $10M+ | âœ… No breach risk |
| âŒ State-by-state regulations | âœ… Uniform nationwide |
| âŒ Slow innovation (legal review) | âœ… Fast iteration |
| âŒ Cross-site data sharing blocked | âœ… Network benchmarking enabled |
| âŒ Competing with Epic, Cerner | âœ… Blue ocean (no competitors) |

**The Insight:**  
*"Benchmarking doesn't need PHI. Removing PHI removes 90% of our risk and 100% of our regulatory burden."*

**Precedent:**  
- Dr. Fadiman: 17 years, zero PHI, massive impact
- Consumer genomics: 23andMe built $3B company on aggregated, de-identified data

---

## SLIDE 9: THE PRIVACY ARCHITECTURE

### **How We Enable Benchmarking Without PHI**

**What We DON'T Collect:**
- âŒ Names, emails, phone numbers
- âŒ Addresses, dates of birth
- âŒ Medical record numbers
- âŒ Exact dates (year only)
- âŒ Free-text clinical notes

**What We DO Collect:**
- âœ… Age ranges (36-45, not exact age)
- âœ… Structured protocols (substance ID, dose, route)
- âœ… Standardized outcomes (PHQ-9, MEQ-30)
- âœ… Hashed subject IDs (within-site tracking only)
- âœ… Aggregated statistics (Nâ‰¥10 minimum)

**The Result:**
- Practitioners can track subjects across sessions (hashed ID)
- Network can benchmark outcomes (aggregated data)
- Zero PHI = Zero HIPAA risk

**Technical Implementation:**
- Small-cell suppression enforced in SQL (Nâ‰¥10)
- No cross-site subject linking
- Safe Harbor compliance by design

---

## SLIDE 10: THE MARKET OPPORTUNITY

### **Total Addressable Market (TAM)**

**Conservative Estimate:**
- 3,500 interventional mood treatment sites (US)
- $600/site/month average
- **TAM: $25.2M ARR**

**Reality Check:**  
*"This is NOT a billion-dollar SaaS TAM. This is a focused, defensible market."*

---

### **Serviceable Available Market (SAM) - 24 Months**
- 400-800 sites realistically serviceable
- **SAM: $2.9M - $5.8M ARR**

---

### **Serviceable Obtainable Market (SOM) - 24 Months**
- 50-150 paying sites (realistic goal)
- 5-20 multi-site operators (anchor customers)
- **SOM: $360K - $1.1M ARR**

**Pricing Strategy:**
- Free tier: Read-only demo dashboards
- Clinic Basic: $399/site/month (site-only dashboards)
- **Clinic Benchmark: $999/site/month** (network intelligence) â† Our focus
- Enterprise: $2K-$10K/month (multi-site rollups)

**Why $999/month works:**  
*"Clinical decision support is worth 3x more than data entry tools"*

---

## SLIDE 11: GO-TO-MARKET STRATEGY

### **Phase 1: Proof of Concept (Q1 2026)**
**Target:** 1-5 "lighthouse" practitioners

- âœ… Dr. Shena Jaramillo (Bend Ketamine Clinic) - Committed
- ğŸ¯ MAPS conference attendees (10,000+ practitioners)
- ğŸ¯ Oregon psilocybin service centers (licensed, data-hungry)
- ğŸ¯ Colorado DORA-approved training cohorts

**Deliverable:** Working demo + 5 case studies

---

### **Phase 2: Network Density (Q2-Q3 2026)**
**Target:** 20-50 sites (critical mass for benchmarking)

**Channels:**
- Training cohorts (built-in user acquisition)
- MAPS/ASKP conference presentations
- Practitioner referrals ("give-to-get" model)
- Content marketing (SEO for "ketamine outcomes tracking")

**Milestone:** Nâ‰¥10 for most common protocols (benchmarks go live)

---

### **Phase 3: Scale (Q4 2026 - 2027)**
**Target:** 100-150 sites

**Virality Mechanism:**
- Benchmark badges for clinic marketing
- "Your clinic vs network" competitive dynamics
- Training programs require participation
- Insurance/compliance benefits

**Revenue Model:** $999/site/month Ã— 100 sites = **$1.2M ARR**

---

## SLIDE 12: COMPETITIVE LANDSCAPE

### **Why Competitors Can't Copy This**

| **Competitor** | **Model** | **Why They Can't Do This** |
|----------------|-----------|----------------------------|
| **Osmind** | EHR for psychedelic therapy | PHI model blocks cross-site benchmarking |
| **Epic/Cerner** | Enterprise EHR | Not psychedelic-specific, no benchmarking |
| **SimplePractice** | Practice management | Not clinical intelligence, no outcomes focus |
| **Academic Research** | Clinical trials | Too slow, not real-time, not practitioner-facing |

**Our Blue Ocean:**
- Psychedelic-specific exposure modeling
- Real-time benchmarking (not retrospective research)
- No-PHI architecture (enables cross-site data)
- Practitioner-facing (not researcher-facing)

**First-Mover Advantage:**  
*"The first platform to hit N=1,000 protocols becomes the standard"*

---

## SLIDE 13: CLINICAL VALIDATION

### **Why Practitioners Will Use This**

**Pain Points We Solve:**

1. **"Am I doing this right?"**  
   â†’ Network benchmarks show your clinic vs peers

2. **"What dose should I use?"**  
   â†’ Similar patients data shows what worked

3. **"Is this interaction dangerous?"**  
   â†’ Safety alerts flag drug interactions

4. **"How do I explain this to my patient?"**  
   â†’ Patient-facing view shows evidence

5. **"Will this work for this patient?"**  
   â†’ Predictive modeling shows probabilities

**Validation:**
- Dr. Shena (first user): "Hit the nail on the head"
- Dr. Fadiman precedent: 17 years proves demand
- MAPS conference growth: 800 â†’ 10,000 attendees (field is ready)

---

## SLIDE 14: RESEARCH ACCELERATION

### **Why This Matters for the Field**

**Current State:**
- Clinical trials: 5-10 years, $10M+, N=100-500
- Publication lag: 2-3 years from data to journal
- Generalizability: Controlled settings â‰  real-world

**Our Model:**
- Real-world evidence: Continuous, $0 marginal cost, N=5,000+
- Publication lag: Real-time dashboards
- Generalizability: Actual clinical practice

**Impact:**
- **Protocol optimization:** Identify best practices 10x faster
- **Safety signals:** Detect adverse events earlier
- **Legislative change:** Compelling evidence for policymakers
- **Insurance coverage:** Real-world outcomes data

**The Vision:**  
*"Turn every clinical encounter into a research contribution"*

---

## SLIDE 15: REGULATORY POSITIONING

### **How We Navigate the Legal Landscape**

**Federal Illegality Challenge:**
- Psilocybin: Schedule I (federally illegal)
- Collecting PHI on illegal substances = legal exposure

**Our Solution:**
- No PHI = No federal exposure
- State-legal substances (ketamine, Oregon psilocybin) = safe
- Research framing: "Quality improvement," not "treatment"

**Legal Precedents:**
- Dr. Fadiman: 17 years, no legal issues
- Hemp Farm Bill: 0.3% THC loophole (cannabinoid data safe)
- Right to Try: Terminal patients have expanded access

**Regulatory Strategy:**
- Start with ketamine (federally legal)
- Expand to Oregon psilocybin (state-legal)
- Position as "research infrastructure," not "medical device"
- Avoid treatment efficacy claims

**Risk Mitigation:**
- No prescribing authority
- No diagnosis
- No guaranteed outcomes
- Language: "Tracks outcomes" not "improves outcomes"

---

## SLIDE 16: THE TEAM & ADVISORS

### **Who's Building This**

**Founder:**
- Trevor Calton
- [Your background - keep brief, credibility-focused]

**Clinical Advisors:**
- Dr. Shena Jaramillo (Bend Ketamine Clinic, MAPS veteran)
- [Other advisors if you have them]

**Technical Infrastructure:**
- Supabase (Postgres, RLS, real-time)
- React/TypeScript frontend
- No-PHI architecture by design

**What We Need:**
- Clinical network partners (beta sites)
- Strategic advisors (NIH, MAPS, training orgs)
- [Funding if applicable]

---

## SLIDE 17: TRACTION & MILESTONES

### **Where We Are Today**

**Completed:**
- âœ… Market research (12 VoC documents, 257 pages)
- âœ… Technical architecture (Supabase, React, RLS)
- âœ… Database schema (17 migrations, no-PHI design)
- âœ… First clinical advisor (Dr. Shena Jaramillo)
- âœ… Strategic positioning (Clinical Intelligence Platform)

**In Progress:**
- ğŸ”„ UI/UX design (split-screen clinical intelligence)
- ğŸ”„ Real-time benchmarking queries (<1 sec performance)
- ğŸ”„ Receptor impact visualization
- ğŸ”„ Predictive outcome modeling

**Next 90 Days:**
- Feb 15: Dr. Shena demo
- Mar 1: Beta launch (5-10 sites)
- Apr 1: Network benchmarks go live (Nâ‰¥10)
- May 1: MAPS conference presentation

---

## SLIDE 18: THE ASK

### **How You Can Help**

**For Clinical Network Owners:**
- Become a beta site (free during pilot)
- Provide clinical feedback
- Refer other practitioners

**For NIH Leadership:**
- Strategic guidance on research positioning
- Connections to training programs
- Validation of clinical utility

**For Strategic Partners:**
- Advisory board participation
- Conference presentation opportunities
- Co-marketing partnerships

**What We Offer:**
- Early access to network benchmarks
- Co-authorship on publications
- Influence on product roadmap

---

## SLIDE 19: THE VISION (5 Years)

### **Where This Goes**

**Year 1 (2026):**
- 50-150 sites
- 5,000+ protocols logged
- Ketamine + Oregon psilocybin focus

**Year 2-3 (2027-2028):**
- 500+ sites
- 50,000+ protocols
- Expand to MDMA (if FDA approved)
- International expansion (Canada, Netherlands)

**Year 5 (2030):**
- 1,000+ sites
- 500,000+ protocols
- **The** standard for psychedelic outcomes tracking
- Real-time research infrastructure for the field
- Evidence base for insurance coverage
- Data-driven legislative change

**The Endgame:**  
*"Every psychedelic treatment in the world contributes to our collective understanding of what works"*

---

## SLIDE 20: WHY NOW?

### **The Convergence**

**Clinical Momentum:**
- MAPS conference: 800 â†’ 10,000 attendees (10x growth)
- Oregon psilocybin: Licensed service centers operational
- Ketamine clinics: 3,500+ sites nationwide
- FDA approvals: MDMA likely 2024-2025

**Regulatory Shift:**
- State-level legalization accelerating
- "Gray market healers" â†’ licensed prescribers
- Demand for clinical rigor and data

**Technology Enablement:**
- Real-time databases (Supabase)
- No-PHI architecture possible
- Sub-second aggregation queries

**Market Readiness:**
- Practitioners want standardized tools
- "Tragically sad" lack of common framework (Dr. Shena)
- Dr. Fadiman proved demand for systematic data collection

**The Window:**  
*"First platform to hit critical mass (N=1,000) becomes the standard. That window is 12-24 months."*

---

## SLIDE 21: CLOSING

# **PPN Research Portal**
## *"See what works. Before you treat."*

**The Opportunity:**
- Transform psychedelic therapy from art to science
- Accelerate research by 10-20 years
- Enable data-driven clinical decisions
- Build the infrastructure the field desperately needs

**The Moat:**
- Network effects compound over time
- First-mover advantage in benchmarking
- No-PHI architecture competitors can't copy

**The Ask:**
- Join us as a beta partner
- Advise on clinical utility
- Help us build the future of psychedelic therapy

---

**Contact:**  
Trevor Calton  
[Email]  
[Phone]  
[Website]

**Next Steps:**  
- Schedule demo (Dr. Shena demo: Feb 15)
- Discuss beta partnership
- Advisory board participation

---

## APPENDIX: TECHNICAL DEEP DIVE

### **Database Architecture**

**Tables:**
- `log_planned_protocols` - Protocols BEFORE treatment
- `log_clinical_records` - Actual treatments delivered
- `log_protocol_comparisons` - Planned vs Actual
- `log_outcomes` - Standardized outcome measures
- `ref_*` tables - Controlled vocabularies

**Performance:**
- Materialized views for common queries
- Redis caching (60 sec TTL)
- Composite indexes for benchmarking
- Target: <1 second query response

**Privacy:**
- Small-cell suppression (Nâ‰¥10) enforced in SQL
- Hashed subject IDs (within-site only)
- No cross-site subject linking
- Safe Harbor compliance

---

## APPENDIX: SAMPLE BENCHMARKING QUERY

```sql
-- Similar Patients Outcomes
SELECT 
  COUNT(*) AS total_count,
  outcome_category,
  COUNT(*) * 100.0 / SUM(COUNT(*)) OVER () AS percentage
FROM (
  SELECT 
    CASE 
      WHEN (phq9_baseline - phq9_4week) / phq9_baseline >= 0.5 THEN 'significant'
      WHEN (phq9_baseline - phq9_4week) / phq9_baseline >= 0.25 THEN 'moderate'
      ELSE 'minimal'
    END AS outcome_category
  FROM log_planned_protocols lp
  JOIN log_outcomes lo USING (clinical_record_id)
  WHERE 
    substance_id = $1 
    AND indication_id = $2
    AND age_range = $3
    AND status = 'completed'
) outcomes
GROUP BY outcome_category
HAVING COUNT(*) >= 10; -- Small-cell suppression
```

**Result:**
- N=127, 68% significant improvement
- N=127, 24% moderate improvement
- N=127, 8% minimal improvement

---

**END OF DECK**

---

## PRESENTATION NOTES

### **For NIH Leadership:**
- Emphasize research acceleration (10x faster than trials)
- Highlight real-world evidence vs controlled trials
- Stress no-PHI architecture (regulatory advantage)
- Position as research infrastructure, not product

### **For Clinical Network Owners:**
- Emphasize clinical utility (decision support)
- Highlight network benchmarks (competitive advantage)
- Stress practitioner time savings (<2 min data entry)
- Position as quality improvement tool

### **For Strategic Partners:**
- Emphasize network effects (first-mover advantage)
- Highlight training cohort integration
- Stress co-marketing opportunities
- Position as field-building infrastructure

### **Objection Handling:**

**"Why not just use an EHR?"**
â†’ EHRs can't do cross-site benchmarking (PHI blocks it)

**"What about Osmind?"**
â†’ They're an EHR (PHI model), we're a benchmarking network (no-PHI model)

**"How do you make money?"**
â†’ $999/site/month for network benchmarks (3x higher than data entry tools)

**"What if practitioners don't adopt?"**
â†’ Dr. Fadiman proved demand (17 years, voluntary participation)

**"What about liability?"**
â†’ No PHI = No HIPAA = No breach risk (strategic advantage)

---

**Deck Created:** 2026-02-11 17:10 PST  
**Version:** 1.0 - Executive Briefing  
**Audience:** NIH Leadership, Clinical Network Owners, Strategic Partners  
**Next Update:** After Dr. Shena demo (Feb 15)
